Parallax Volatility Advisers, L.P. Madrigal Pharmaceuticals, Inc. Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $1,314 - $2,032	9 New	9 $1,000
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $712,589 - $947,034	3,084 New	3,084 $747,000
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $13,578 - $21,232	-149 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$103.48 - $143.84 $209,029 - $290,556	-2,020 Reduced 93.13%	149 $19,000
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $205,556 - $467,506	2,169 New	2,169 $244,000
Q1 2018 May 15, 2018	SELL	$93.35 - $149.04 $58,810 - $93,895	-630 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $24,790 - $61,343	630	630 $58,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.